| خلاصه مقاله | Purpose: Lower urinary tract symptoms (LUTS) is prevalent among patients with multiple sclerosis (MS). This study aims to evaluate the efficacy and safety of different methods in MS-related LUTS.
Methods: This study was conducted following the PRISMA statement. Systematic review studies which reported the efficacy and/or safety of a method for LUTS in MS are considered for inclusion in this study. A systematic search was conducted in PubMed, Scopus, Embase, Web of Science, and Cochrane databases with ('Multiple Sclerosis') AND (bladder OR urin*) AND ('systematic review') keywords in March 2023. The risk of bias is assessed using the Joanna Briggs Institute (JBI) critical appraisal checklist for systematic reviews.
Results: Out of 348 results of database searches, 31 systematic reviews were included in this umbrella review. There is little evidence that reported appropriate efficacy and safety for alpha-blockers (indoramin, phenoxybenzamine, and tamsulosin), anticholinergics, desmopressin, intravesical vanilloids, mirabegron, stem cell therapies, neurotoxin treatments, cannabinoids, transcranial magnetic stimulation, and craniosacral therapy, and catheterization. In addition, peripheral nerve stimulations (sacral neuromodulation, spinal cord stimulation, tibial nerve stimulation) and pelvic floor muscle training are also found to be effective and safe in MS patients.
Conclusion: Although, a high prevalence of LUTS in MS patients, there is a lack of well-designed randomized controlled trials (RCTs) regarding the management of MS-related LUTS, which makes evidence inconclusive. There is a need for future multi-center studies on this topic.
Funding acknowledgments: The research protocol was approved and supported by the Student Research Committee, Tabriz University of Medical Sciences (grant number: 71911). |